Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.35 USD
Change Today +0.10 / 4.44%
Volume 37.6K
RCPI On Other Exchanges
As of 1:19 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

rock creek pharmaceuticals i (RCPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/11/14 - $20.00
52 Week Low
05/1/15 - $2.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

rock creek pharmaceuticals i (RCPI) Related Businessweek News

View More BusinessWeek News

rock creek pharmaceuticals i (RCPI) Details

Rock Creek Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health. Its lead drug candidate is anatabine citrate that is in Phase I clinical trials, a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida.

rock creek pharmaceuticals i (RCPI) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $600.0K
President and Director
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

rock creek pharmaceuticals i (RCPI) Key Developments

Rock Creek Pharmaceuticals, Inc. Appoints Sunitha Chundru Samuel as Director

Rock Creek Pharmaceuticals, Inc. announced that the company has made a key independent appointment to the company's Board of Directors with the recent election of Dr. Sunitha Chundru Samuel as a new director. Dr. Samuel has been the Chief Executive Officer of Sierra Molecular Corporation, where Dr. Samuel also serves on its board of directors.

Rock Creek Pharmaceuticals, Inc. Approves Amendment to Tenth Amended and Restated Certificate of Incorporation

Rock Creek Pharmaceuticals, Inc. announced that at the Annual Meeting held on April 10, 2015 approved amendment to the company's tenth amended and restated certificate of incorporation, as amended, to effect the reverse stock split.

Rock Creek Pharmaceuticals, Inc. Announces Resignation of Edward J. McDonnell as Directors

On April 2, 2015, the Board of Directors of Rock Creek Pharmaceuticals, Inc. received resignation message from Edward J. McDonnell notifying the company of Mr. McDonnell's resignation from his position on the Board of Directors over a disagreement regarding the company's drug development regulatory strategy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCPI:US $2.35 USD +0.10

RCPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCPI.
View Industry Companies

Industry Analysis


Industry Average

Valuation RCPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCK CREEK PHARMACEUTICALS I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at